Type 1 diabetes

Characteristics of autoantibody-positive individuals without high-risk HLA-DR4-DQ8 or HLA-DR3-DQ2 haplotypes

DiabetologiaPublished Cross-sectional study

Authors' conclusion

Autoantibody-positive individuals who lack both high-risk HLA haplotypes (DRX/DRX) or have HLA-DR3-DQ2 but lack HLA-DR4-DQ8 (DR3/non-DR4) have phenotypic differences compared with DR3/DR4 and DR4/non-DR3 individuals, suggesting that there is aetiological heterogeneity in type 1 diabetes.

Study context

Population
Islet autoantibody-positive relatives of individuals with T1D
Participants
1,263 / 2,340 / 1,607 / 1,294
Exposure
Autoantibody-positive relatives grouped by HLA haplotype: DRX/DRX vs DR3/DR4, DR4/non-DR3 and DR3/non-DR4
  • DR3/DR4n = 1,263
  • DR4/non-DR3n = 2,340
  • DR3/non-DR4n = 1,607
  • DRX/DRXn = 1,294reference
Outcome
IA-2A prevalence at enrolment
Follow-up
Enrolment

Main finding

As reported in the abstract

DRX/DRX vs DR4/non-DR3: P < 0.001 · DRX/DRX vs DR3/DR4: P < 0.001

Observational data: associations, not effects.

Further findings

IAA prevalence at enrolment

IAA prevalence at enrolment — IAA% similar in DRX/DRX, DR4/non-DR3 and DR3/DR4, lower in DR3/non-DR4
p<0.001

Demographic and metabolic characteristics

DRX/DRX vs DR3/DR4: older, fewer White, more overweight/obesity, higher preserved C-peptide (lower Index60)
all p<0.005
DRX/DRX vs DR3/non-DR4: younger, more Hispanic, lower Index60
all p<0.005
DRX/DRX vs DR4/non-DR3: fewer White or non-Hispanic, lower Index60

Progressors to clinical T1D

Participants who progressed to clinical T1D
1292
DR3/non-DR4: higher GADA%, lower IA-2A% and lower IAA% than other groups
all p<0.01
DR3/DR4: youngest age at diagnosis
all p<0.001

Original publication

Characteristics of autoantibody-positive individuals without high-risk HLA-DR4-DQ8 or HLA-DR3-DQ2 haplotypes. Diabetologia. Published 13 December 2024. doi:10.1007/s00125-024-06338-7

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.